This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Nodular Lymphoma — Evidence for Origin from Follicular B Lymphocytes

List of authors.
  • Elaine S. Jaffe, M.D.,
  • Ethan M. Shevach, M.D.,
  • Michael M. Frank, M.D.,
  • Costan W. Berard, M.D.,
  • and Ira Green, M.D.

Abstract

To investigate the cellular origin of nodular lymphoma, neoplastic cells from six patients with nodular lymphomas were studied both in cell suspensions and in frozen tissue sections for (1) the C3 receptor — red cells coated with antibody and complement (IgMEAC) — of B lymphocytes, (2) the receptor for cytophilic antibody — red cells coated with IgG (IgGEA) — of histiocytes, and (3) spontaneous rosette formation with sheep erythrocytes characteristic of T lymphocytes. A high proportion of the neoplastic cells in suspension bound IgMEAC. They did not bind IgGEA and did not form sheep erythrocyte rosettes. In tissue sections of nodular lymphomas the IgMEAC reagent bound to the neoplastic nodules. In control lymph nodes and spleens these binding properties were demonstrated to be characteristic of the cells of the lymphoid follicle, thus suggesting a follicular B-cell origin for nodular lymphomas. (N Engl J Med 290:813–819, 1974)

Funding and Disclosures

* Grand Island Biological Co., Grand Island, N.Y.

† Pharmacia Fine Chemicals, Piscataway, N.J.

‡ Hypaque-M, 90 per cent, Winthrop Laboratories, New York, N.Y.

We are grateful to Mrs. Eileen Sussman for technical assistance and to Mr. Ralph Isenburg for photographic assistance, both of the Laboratory of Pathology of the National Cancer Institute.

Author Affiliations

From the Hematopathology Section. Laboratory of Pathology, National Cancer Institute, the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, and the Laboratory of Clinical Investigation. National Institute of Allergy and Infectious Diseases (address reprint requests to Dr. Jaffe at the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014).

Print Subscriber? Activate your online access.